Clinical trials: Oral Contrast
Patients Requiring Abdominopelvic CT With Oral Administration of Contrast
Study With Oral Isovue in Abdominopelvic CT
This is a retrospective clinical study with prospectively designed blinded evaluation of CT images in adult and pediatric patients who underwent CT examinations of the abdomen and pelvis and were orally administered a solution of…
- Trial name
- NCT04453059
- Testing
- Iopamidol
- Where
- United States
- Volunteers
- 218 people
- Sponsor
- Bracco Diagnostics, Inc
Unspecified Disorder of Stomach and Duodenum
A Study to Evaluate the Safety and Efficacy of Oral Contrast Agent for Sonography
The goal of this clinical trial is to verify the safety and efficacy of Oral Contrast Agent for Sonography produced by Shandong Baiduo Medical Instruments Co., LTD.
- Trial name
- NCT05676164
- Testing
- KANG XIAN, TIAN XIA
- Where
- China
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Shandong Branden Med.Device Co.,Ltd
Healthy
A Healthy Volunteer Trial Investigating MR-enterography Image Quality of Lumentin® 44
A healthy volunteer, open, PoC single center trial investigating a new oral contrast agent for use in combination of MR examination of the abdomen and pelvis.
- Trial name
- NCT05781490
- Testing
- Lumentin® 44 Powder for oral foam
- Where
- Sweden
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Lument AB
GI Carcinoma, GI Disorders
Phase 2 Study of NX9 for Delineation of Bowel Anatomy
This study will evaluate marking and distention of the bowel of the oral contrast agent, NX9, at CT of the abdomen and pelvis, VLDCT with no contrast will be followed by VLDCT with NX9 contrast followed by CT with NX9 and…
- Trial name
- NCT04789200
- Testing
- NX9 Oral Contrast Agent
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Nextrast, Inc.
Abdominal Pain
Study to Evaluate the Efficacy and Safety of Hyoscine Butylbromide Tablets for the Treatment of Occasional or Recurrent Episodes of Gastric or Intestinal Spasm-like Pain or Discomfort
In contrast with Hyoscine Butylbromide Capsule 10mg, Study is to evaluate the efficacy and safety of Hyoscine Butylbromide tablets 10 mg (20mg, 3 times daily, orally) over a period of 3 days for the treatment of occasional or…
- Trial name
- NCT02242305
- Testing
- Hyoscine Butylbromide - Tablet, Hyoscine Butylbromide - Capsule
- Volunteers
- 302 people
- Sponsor
- Boehringer Ingelheim
Multiple Sclerosis, Optic Nerve
Single Oral Doses Study of Nerispirdine on Visual Function in Patients With Multiple Sclerosis
The primary objective of the study was to evaluate the effect of Nerispirdine (50 mg or 400 mg) and placebo given orally as a single dose once a week in crossover design on latency of Visual Evoked Potentials (VEP) P100 in optic…
- Conditions
- Multiple Sclerosis, Optic Nerve, Neuritis
- Trial name
- NCT00772525
- Testing
- Nerispirdine
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Sanofi